Publication

Re-implantation after insufficient primary 125-i permanent prostate brachytherapy

Journal Paper/Review - Aug 6, 2013

Units
PubMed
Doi
Contact

Citation
Putora P, Plasswilm L, Seelentag W, Schiefer J, Markart P, Schmid H, Engeler D. Re-implantation after insufficient primary 125-i permanent prostate brachytherapy. Radiat Oncol 2013; 8:194.
Type
Journal Paper/Review (English)
Journal
Radiat Oncol 2013; 8
Publication Date
Aug 6, 2013
Issn Electronic
1748-717X
Pages
194
Brief description/objective

INTRODUCTION
We describe five patients receiving a re-implantation (RI) after post-operative dosimetry of the primary 125-I permanent prostate brachytherapy (BT) for prostate cancer revealed an insufficient dose coverage.

MATERIALS AND METHODS
Five out of 222 consecutive patients treated (from March, 2001 to August, 2012) with 125-I BT, received a RI after dosimetric verification by CT and MRI fusion four to eight weeks after implantation displayed an insufficient dose coverage. RIs were performed with 10 to 19 seeds, three to four months after primary intervention. Dosimetry after RI showed an improved and sufficient total dose coverage in all patients.

RESULTS
At last follow-up (18 to 99 months, median 57 months), none of the patients had relevant implant associated side-effects. Functional outcome was comparable to patients after one-time implantation. PSA levels post intervention showed a decreasing tendency in 4 patients. One patient had a local recurrence after 12 months.

CONCLUSION
In our series, approximately 2% of the patients treated with permanent prostate BT required a RI due to insufficient dose coverage. None of the patients who underwent RI experienced complications. Our series, although only with 5 cases and limited follow-up, along with other published reports, demonstrates good tolerability.